Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6442102rdf:typepubmed:Citationlld:pubmed
pubmed-article:6442102lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:6442102lifeskim:mentionsumls-concept:C1522449lld:lifeskim
pubmed-article:6442102lifeskim:mentionsumls-concept:C0600139lld:lifeskim
pubmed-article:6442102lifeskim:mentionsumls-concept:C0227963lld:lifeskim
pubmed-article:6442102lifeskim:mentionsumls-concept:C0021102lld:lifeskim
pubmed-article:6442102lifeskim:mentionsumls-concept:C2699153lld:lifeskim
pubmed-article:6442102lifeskim:mentionsumls-concept:C0547040lld:lifeskim
pubmed-article:6442102lifeskim:mentionsumls-concept:C0796396lld:lifeskim
pubmed-article:6442102lifeskim:mentionsumls-concept:C1269955lld:lifeskim
pubmed-article:6442102lifeskim:mentionsumls-concept:C1704229lld:lifeskim
pubmed-article:6442102lifeskim:mentionsumls-concept:C1705604lld:lifeskim
pubmed-article:6442102lifeskim:mentionsumls-concept:C1314939lld:lifeskim
pubmed-article:6442102lifeskim:mentionsumls-concept:C0443268lld:lifeskim
pubmed-article:6442102pubmed:issue6lld:pubmed
pubmed-article:6442102pubmed:dateCreated1985-4-15lld:pubmed
pubmed-article:6442102pubmed:abstractTextSixty-three consecutive patients with cancer of the prostate treated by pelvic lymphadenectomy, I-125 implantation +/- Co60 therapy were studied regarding the impact of extension of cancer beyond the capsule and minimal nodal involvement. Extension of cancer beyond the prostatic capsule, Stage T3, constituted 34%, while Stages T0-2 comprised 66% of the cases. The features of T3 compared with T2 or less were: higher incidence of younger age (50s), 29% vs. 19%; less well-differentiated cancer, 29% vs. 64%; higher incidence of pelvic node involvement, 52% vs. 18%; and higher incidence of recurrence, 24% vs. 4.7%. The involvement of only one or two pelvic nodes by microscopic cancer did not adversely affect the prognosis in T2 group over a relatively short period of follow-up. No local recurrence occurred in T2. In the T3 group, two of 21 (9.5%) developed local recurrence.lld:pubmed
pubmed-article:6442102pubmed:languageenglld:pubmed
pubmed-article:6442102pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6442102pubmed:citationSubsetIMlld:pubmed
pubmed-article:6442102pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6442102pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6442102pubmed:statusMEDLINElld:pubmed
pubmed-article:6442102pubmed:monthDeclld:pubmed
pubmed-article:6442102pubmed:issn0277-3732lld:pubmed
pubmed-article:6442102pubmed:authorpubmed-author:WeinsteinS...lld:pubmed
pubmed-article:6442102pubmed:authorpubmed-author:AbadirRRlld:pubmed
pubmed-article:6442102pubmed:authorpubmed-author:RossGGJrlld:pubmed
pubmed-article:6442102pubmed:issnTypePrintlld:pubmed
pubmed-article:6442102pubmed:volume7lld:pubmed
pubmed-article:6442102pubmed:ownerNLMlld:pubmed
pubmed-article:6442102pubmed:authorsCompleteYlld:pubmed
pubmed-article:6442102pubmed:pagination713-7lld:pubmed
pubmed-article:6442102pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:6442102pubmed:meshHeadingpubmed-meshheading:6442102-...lld:pubmed
pubmed-article:6442102pubmed:meshHeadingpubmed-meshheading:6442102-...lld:pubmed
pubmed-article:6442102pubmed:meshHeadingpubmed-meshheading:6442102-...lld:pubmed
pubmed-article:6442102pubmed:meshHeadingpubmed-meshheading:6442102-...lld:pubmed
pubmed-article:6442102pubmed:meshHeadingpubmed-meshheading:6442102-...lld:pubmed
pubmed-article:6442102pubmed:meshHeadingpubmed-meshheading:6442102-...lld:pubmed
pubmed-article:6442102pubmed:meshHeadingpubmed-meshheading:6442102-...lld:pubmed
pubmed-article:6442102pubmed:meshHeadingpubmed-meshheading:6442102-...lld:pubmed
pubmed-article:6442102pubmed:meshHeadingpubmed-meshheading:6442102-...lld:pubmed
pubmed-article:6442102pubmed:meshHeadingpubmed-meshheading:6442102-...lld:pubmed
pubmed-article:6442102pubmed:meshHeadingpubmed-meshheading:6442102-...lld:pubmed
pubmed-article:6442102pubmed:meshHeadingpubmed-meshheading:6442102-...lld:pubmed
pubmed-article:6442102pubmed:meshHeadingpubmed-meshheading:6442102-...lld:pubmed
pubmed-article:6442102pubmed:meshHeadingpubmed-meshheading:6442102-...lld:pubmed
pubmed-article:6442102pubmed:year1984lld:pubmed
pubmed-article:6442102pubmed:articleTitleI-125 implant and supervoltage irradiation for treatment of T0-2 or T3 carcinoma of the prostate. The impact of invasion beyond the prostatic capsule and minimal nodal involvement.lld:pubmed
pubmed-article:6442102pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6442102pubmed:publicationTypeComparative Studylld:pubmed